- Home
- STRO vs ZURA Comparison
STRO vs ZURA Comparison
Compare STRO & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRO | ZURA |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | United States | United States |
| Employees | 131 | 30 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.9M | 521.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | STRO | ZURA |
|---|---|---|
| Price | $23.85 | $6.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $26.38 | $11.78 |
| AVG Volume (30 Days) | 160.6K | ★ 514.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.52 | $0.99 |
| 52 Week High | $27.96 | $7.25 |
Technical Indicators
Market Signals| Indicator | STRO | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 57.93 | 49.48 |
| Support Level | $0.76 | $5.49 |
| Resistance Level | $27.96 | $6.99 |
| Average True Range (ATR) | 2.05 | 0.49 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 67.80 | 60.14 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.